Neutrophils contribute to demyelinating autoimmune diseases, yet their phenotype and functions have been elusive to date. Here, we demonstrate that ICAM1 surface expression distinguishes extra-from intravascular neutrophils in the mouse CNS during experimental autoimmune encephalomyelitis (EAE). Transcriptomic analysis of these 2 subpopulations indicated that neutrophils, once extravasated, acquire macrophage-like properties, including the potential for immunostimulation and MHC class II-mediated antigen presentation. In corroboration, super-resolution (3D stimulated emission-depletion [STED]) microscopy revealed neutrophils forming synapses with T and B cells in situ. Further, neutrophils specifically express the aspartic retroviral-like protease ASPRV1, which increases in the CNS during EAE and severe cases of multiple sclerosis. Without ASPRV1, mice immunized with a new B cell-dependent myelin antigen (but not with the traditional myelin oligodendrocyte glycoprotein peptide) develop a chronic phase of EAE that is less severe and even completely fades in many individuals. Therefore, ICAM1 + macrophage-like neutrophils can play both shared and nonredundant roles in autoimmune demyelination, among them perpetuating inflammation via ASPRV1.
Introduction
People with demyelinating autoimmune diseases, such as multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM), have a corrupted immune system that destroys the myelin sheath of neurons in the CNS. The root causes of these diseases remain unknown, but the underlying molecular and cellular mechanisms are fairly well comprehended, owing to the animal model experimental autoimmune encephalomyelitis (EAE). EAE can be induced in mice by immunization with different myelin antigens (e.g., myelin oligodendrocyte glycoprotein [MOG] ) (1) . Similarly to its human counterparts, EAE can comprise 5 phases: (i) a preclinical induction phase, in which CD4 + Th cells are primed in lymphoid organs by antigen-presenting cells (e.g., DCs, B cells) and traffic toward the CNS (2); (ii) an onset phase, in which Th cells are licensed at the CNS interface to enter the parenchyma and initiate inflammation (3); (iii) an acute attack phase, in which myeloid cells (e.g., macrophages) execute effector functions resulting in demyelination (4); (iv) a recovery phase, in which immunoregulatory cells act to resolve inflammation either partially or completely (5) ; and (v) a chronic phase, in which corrupted immune cells succeed in perpetuating the inflammation. The mechanism responsible for the progression of acute to chronic inflammation is unknown yet critical for understanding and treating autoimmune diseases.
The past decade of research has unmasked a new player in autoimmune demyelination: the neutrophil granulocyte. As discussed in a recent review (6) , this type of myeloid cell is observed in the CNS during Neutrophils contribute to demyelinating autoimmune diseases, yet their phenotype and functions have been elusive to date. Here, we demonstrate that ICAM1 surface expression distinguishes extra-from intravascular neutrophils in the mouse CNS during experimental autoimmune encephalomyelitis (EAE). Transcriptomic analysis of these 2 subpopulations indicated that neutrophils, once extravasated, acquire macrophage-like properties, including the potential for immunostimulation and MHC class II-mediated antigen presentation. In corroboration, superresolution (3D stimulated emission-depletion [STED]) microscopy revealed neutrophils forming synapses with T and B cells in situ. Further, neutrophils specifically express the aspartic retrovirallike protease ASPRV1, which increases in the CNS during EAE and severe cases of multiple sclerosis. Without ASPRV1, mice immunized with a new B cell-dependent myelin antigen (but not with the traditional myelin oligodendrocyte glycoprotein peptide) develop a chronic phase of EAE that is less severe and even completely fades in many individuals. Therefore, ICAM1
+ macrophage-like neutrophils can play both shared and nonredundant roles in autoimmune demyelination, among them perpetuating inflammation via ASPRV1.
NMOSD, ADEM, and severe forms of MS. In the most common forms of MS, neutrophils are typically absent from brains taken at autopsy, usually many years after diagnosis. However, one study reports their presence in the cerebrospinal fluid of early-diagnosed MS patients (7) , and several indirect observations link neutrophils to the most common forms of MS (6) . In EAE pathogenesis, the importance of neutrophils is clear: the disease can be blocked or attenuated by depleting neutrophils or molecules involved in their recruitment (6) . However, their exact functions remain elusive, in part because their phenotype has not yet been characterized and because there is a paucity of biomarkers and genetic deletion tools for neutrophil assessment.
In the present study, we show that neutrophils that infiltrate the spinal cord parenchyma during EAE, but not intravascular neutrophils that crawl on the luminal endothelial surface, bear on their surface the adhesion molecule ICAM1 (CD54). Using this marker, we isolated these 2 neutrophil populations and compared their transcriptomes in order to gain insights into their properties. The results suggest that neutrophils, in EAE, exert macrophage-like functions, as well as a specific effect via the enzyme aspartic peptidase retroviral-like 1 (ASPRV1, also known as SASPase). ASPRV1 is synthesized as a zymogen that contains a putative transmembrane domain and a conserved catalytic domain with a key aspartic acid residue (8) (9) (10) . This zymogen can undergo autocleavage under slightly acidic conditions, releasing the catalytic domain that homodimerizes to form an active protease (8, 9) . ASPRV1 has so far only been detected in stratified epithelia, where it cleaves its only known substrate, profilaggrin (8, 9, 11, 12) . Its knockdown or overexpression causes no major physiological defect (although the skin of adult ASPRV1-deficient mice shows fine wrinkles and reduced hydration) (9, 11, 12) . Here, we demonstrate that ASPRV1 is: (i) only expressed by neutrophils in the immune and nervous systems both in mice and humans and (ii) essential for the progression of acute to chronic inflammation, specifically when EAE is induced with a new MOG antigen that involves -like in MS (13) and contrary to the traditional MOG peptide (14) -a deleterious action of B cells.
Results

ICAM1 distinguishes extra-from intravascular neutrophils in the CNS of EAE mice.
To study the phenotype of neutrophils in EAE, cell-surface markers (CD45, CD11b, Ly6G, ICAM1) were analyzed by flow cytometry in the spinal cord and blood of mice immunized with MOG and adjuvants (i.e., complete Freund's adjuvant and pertussis toxin). Sham-immunized mice (adjuvants only) and naive mice were used as controls. Samples were taken at day 15 after immunization -a time point at which all mice had developed signs of EAE (clinical scores ranging from 0.5-3; mean, 1.9 ± 0.2) and at which neutrophils were expected to be mobilized to the CNS (15) (16) (17) .
As shown in Figure 1 , A and B, neutrophils (CD45
were expanded in the spinal cord and blood of both EAE mice and sham-immunized mice relative to naive controls. While this cell expansion in the blood was comparable between these 2 groups, it was 4.3 times higher in the CNS of EAE mice relative to sham-immunized mice ( Figure 1B) . These results are consistent with the prior observation that neutrophils crawl more frequently on the CNS endothelial surface upon exposure to adjuvants (16, 18, 19) but infiltrate the parenchyma only during EAE (15) (16) (17) .
Interestingly, ICAM1 was highly expressed (median fluorescence intensity [MFI], 2,052 ± 510) on a large proportion of spinal cord neutrophils (64% ± 9%) in EAE, but not in sham ( Figure 1 , C and D, upper panels). ICAM1 was generally not expressed on blood neutrophils, except at low levels (MFI, 84 ± 5) and on a small proportion (13% ± 3%) in EAE and sham ( Figure 1 , C and D, lower panels). In the spinal cord, ICAM1 + neutrophils expressed higher levels of CD11b and CD45 than did ICAM1 -neutrophils ( Figure  2A ). Both populations were identical on the basis of their forward and side scatter properties (data not shown) and nuclear morphologies ( Figure 2 , B and C). Similar observations were made at other time points (e.g., day 12, 24) and in brain samples (data not shown).
To facilitate the anatomical localization of ICAM1 + and ICAM1 -neutrophils, we generated reporter mice with green fluorescent neutrophils by crossing heterozygous Catchup mice (20) (expressing Cre recombinase under the neutrophil-specific Ly6g promoter) with Ai6 mice (21) (expressing ZsGreen fluorescent protein permanently upon Cre activity). Spinal cords were collected for confocal imaging 15 days after EAE induction. In general, ZsGreen + neutrophils (with characteristic multilobed nuclei) were concentrated in inflammatory foci near the central canal and in meningeal and submeningeal areas of the spinal cord ( Figure 3A ). These cells were confirmed to be neutrophils by colocalization of ZsGreen with Ly6G ( Figure  3B ). ICAM1 was detected on capillaries but not on intravascular neutrophils that exhibited the rod-shaped Figure 3C ). In contrast, ICAM1 was detected on the vast majority (>90%) of extravascular neutrophils in the meninges and parenchyma ( Figure 3D ). Neutrophils were also observed in the vasculature of naive and sham-treated mice (where they were negative for ICAM1) but never in the parenchyma, as previously reported (18, 19) .
We conclude the existence of 2 populations of neutrophils in the CNS of EAE mice: one patrols the CNS vasculature by crawling on its inner surface and is characterized by the absence or very low levels of ICAM1; the other, more abundant, is recruited into the meninges and parenchyma by an antigen-driven mechanism and is characterized by strong expression of ICAM1 and higher levels of CD11b and CD45. This phenotype suggests a state of increased activation (23, 24 Unsupervised hierarchical clustering revealed that the transcriptome of ICAM1 + neutrophils was substantially different from that of ICAM1 -neutrophils ( Figure 4A ). Among the 479 genes that were differentially expressed between these cells according to stringent criteria (fold change ≥ 3, mean hybridization signal ≥ 200 in at least 1 subset, P ≤ 0.05), 343 were upregulated and 136 were downregulated in ICAM1 + neutrophils ( Figure  4A and Supplemental Tables 2 and 3 ). Hence, neutrophils are functionally plastic in EAE: after extravasation into the inflamed CNS, they acquire distinct properties through a substantial transcriptional remodeling.
Hierarchical clustering also showed that ICAM1 + neutrophils were more similar to macrophages and DCs than ICAM1 -neutrophils were (see dendrogram in Figure 4A ). Of the 343 genes that were upregulated in ICAM1 + neutrophils (Supplemental Table 2 ), 328 (96%) were also expressed by macrophages and/or DCs at similar or higher levels. Further, 232 (68%) had a known function and could be manually divided into 12 functional categories, including cell-cell or cell-matrix interaction, cytokine-cytokine receptor interaction, and antigen presentation ( Figure 4B ). These 3 latter categories also stood out as overrepresented when the classification was done with software tools (KEGG and Ingenuity Pathway Analysis, P < 0.0001). Notably, they included many genes coding for cytokines (e.g., IL-1α, CSF1), leukocyte chemoattractants (e.g., CXCL9-11, CCL2-5), cell-surface receptors (e.g., CCR2, CCR5, HAVCR2, NIACR1), and adhesion molecules (e.g., VCAN) ( Figure 4C ). Remarkably, ICAM1 + neutrophils upregulated molecules at every step along the antigen-processing and -presentation pathway ( Figure 4C ): proteases that intracellularly process protein antigens (e.g., LGMN, IFI30, CTSB); subunits of the immunoproteasome (e.g., PSMB10); chaperones necessary for MHCII complex formation (e.g., CD74/Ii, H2-DMa); MHCII subunits themselves (H2-Aa, H2-Ab1, H2-Eb1); and costimulatory molecules (e.g., CD40, CD48, CD83, CD86). By flow cytometry, the presence of MHCII and costimulatory molecules was confirmed on a considerable proportion of ICAM1 + neutrophils: 12.5% expressed high levels of MHCII with costimulatory molecules, 50.7% expressed moderate levels of MHCII, and 36.8% were MHCII -( Figure 5 ). These results indicate that neutrophils, after infiltrating the CNS, acquire macrophage/DC properties, including the potential ability to secrete immunostimulatory factors and present antigen to lymphocytes (Figure 4 , E and F).
Another 104 genes were predominantly expressed in neutrophils and either not expressed or weakly expressed in the other myeloid cells ( Figure 4A and Supplemental Table 4 ). Those that were expressed in both neutrophil subsets included genes coding for well-known neutrophil markers (e.g., Ly6G, CXCR2, MMP9), the recently discovered neutrophil cytokine IL-36γ (25) (also called IL1F9), the enzyme histidine decarboxylase (HDC) that synthesizes histamine, and new potential neutrophil markers with unclear functions (e.g., ASPRV1, CHI3L1) ( Figure 4D ). Thirteen of these 104 genes, notably melanoregulin (Mreg) and IL23a ( Figure 4D ), were enriched ≥ 3-fold in ICAM1
+ neutrophils compared with ICAM1 -neutrophils. Thus, it appears that neutrophils are equipped with a specific set of molecules, allowing them to execute unique functions in EAE, in addition to roles redundant with those of macrophages and DCs.
ICAM1 + neutrophils do not differentiate into Ly6G
-monocytic cells. Our microarray and quantitative PCR (qPCR) data revealed that Ly6g mRNA was ~5 times less abundant in ICAM1
+ neutrophils compared with ICAM1 -neutrophils ( Figure 6 , A and B). This observation prompted us to examine whether Ly6G was uniformly distributed among the 3 subpopulations of neutrophils defined by the levels of MHCII. Flow cytometric analysis revealed that Ly6G expression was roughly similar on MHCII -and MHCII mid neutrophils, but 3-fold lower on MHCII hi neutrophils ( Figure 6C ). An intriguing question arises as to whether MHCII hi Ly6G lo neutrophils ultimately go on to lose Ly6G completely. If this were correct, then gating our samples on Ly6G as a neutrophil marker would lead to underestimating the number of infiltrating neutrophils and to excluding a potentially important neutrophil subset. The possibility that neutrophils become negative for Ly6G is supported by an independent study showing that neutrophils can differentiate into Ly6G -monocytic cells under inflammatory conditions in vivo (26) . To test this possibility in EAE, we permanently labeled neutrophils using the Catchup × Ai6 model (described above) and analyzed them by flow cytometry. Approximately 80% of all Ly6G + neutrophils from the spinal cord of EAE mice expressed ZsGreen. Curiously, Ly6G
+ neutrophils accounted for 78% of the ZsGreen + population, while the remaining 22% were other myeloid phagocytes: DCs, macrophages, and microglia ( Figure 6D ). To determine whether this latter result was real differentiation or simply attributable to engulfment of ZsGreen + neutrophil debris, we examined spinal cord sections immunostained for Iba1 (also known as AIF1), a marker of microglia and other myeloid phagocytes (27) . We found that virtually all cells double-positive for ZsGreen and Iba1 were actually cells containing ZsGreen + debris in their cytoplasm ( Figure  6E ). However, we did see a few cells that were truly double-positive with ZsGreen throughout the cytoplasm (data not shown); these cells exhibited a multilobed nucleus, expressed lower levels of Iba1 than other myeloid cells (consistent with our microarray data in Supplemental Table 1 revealing Iba1 expression  in ICAM1 + neutrophils), and accounted for only a minor fraction of ZsGreen + cells (<1%). Thus, we conclude that ICAM1 + neutrophils decrease, but do not lose, their expression of Ly6G during migration into the CNS parenchyma; there, they adopt some macrophage characteristics but do not differentiate into a different myeloid cell type. The diminution of Ly6G expression could still reduce the number of cells estimated by immunofluorescence, due to the lower sensitivity of the technique. Furthermore, flow cytometric analysis of neutrophils in the Catchup × Ai6 model must be done with caution, as a significant proportion of ZsGreen + cells may be contaminated with other myeloid phagocytes that have internalized remnants of dead neutrophils, a phenomenon also observed in stroke (28) .
ICAM1 + neutrophils form immunological synapses with T and B cells.
Our microarray results indicate that infiltrating neutrophils upregulate proteins known to be important for physical and functional interactions with lymphocytes (e.g., ICAM1, MHCII, and costimulatory molecules) (Figure 4 and 5). To determine whether such interactions occur in our model, spinal cord sections from Catchup × Ai6 mice with EAE were stained for CD3ε and B220; then, the number of neutrophils physically contacting lymphocytes was estimated. Figure 7A gives an overview of one such section, where neutrophils and T cells were localized both in the parenchyma and surrounding meninges, whereas most B cells were restricted to the meninges. At higher magnification, we observed -across the tissue -many neutrophils that were juxtaposed to T and B cells ( Figure 7B ). In all individuals studied (4), these contacts were frequent: in the meninges, for example, approximately 36% of ZsGreen only been thus far documented between cytotoxic T cells and astrocytes during infection (31, 32) . To investigate the fine-scale structure of neutrophil−T cell doublets, we performed super-resolution microscopy by stimulated emission-depletion (STED) with a pulsed depletion beam and time-gated detection ( Figure  7D ). Three-dimensional reconstructions revealed the presence of a zone devoid of ICAM1 on neutrophils at the plane of contact with T cells ( Figure 7E ). To our knowledge, this represents the first in vivo evidence that neutrophils form immunological synapses with T cells. Our observations suggest that neutrophils recruited to the mouse CNS during EAE can physically engage with T and B cells and form immunological synapses with T cells, reminiscent of antigen presentation.
To directly test the importance of the antigen-presenting capability of neutrophils in EAE, we crossed Catchup mice to a conditional null strain for H2-Ab1 (33) (the only extant MHCII β-chain allele in C57BL/6 mice and among those genes upregulated in ICAM1 + neutrophils) in order to abolish MHCII expression specifically in neutrophils. Gene deletion (>80%) was confirmed in genomic DNA obtained from spinal cord neutrophils (Supplemental Figure 1A) ; however, perplexingly, H2-Ab1 mRNA and protein were unchanged in the same samples (Supplemental Figure 1, B-D) . Thus, H2-Ab1 adds to a list of proteins that cannot be studied in the Catchup model (20) , perhaps because the deletion is partial, occurs after mRNA transcription, or is bypassed by the acquisition of molecules from other cells (e.g., via trogocytosis or vesicular transfer).
ASPRV1 is specific to neutrophils and increases in the CNS during EAE and severe forms of MS. Seeking to discover a unique function of neutrophils in EAE, we chose to follow up on Asprv1 because it was the most highly expressed neutrophil-specific gene (Supplemental Table 4 ) with a human homolog that had not yet been studied in the immune or nervous system, and because it encodes a little-known protease that could play a novel effector role in inflammation. By qPCR, we found that Asprv1 mRNA was indeed expressed in neutrophils (ICAM1 + and ICAM1 -) extracted by FACS from EAE spinal cords but not in any other immune cell types tested ( Figure 8A ). ASPRV1 protein was also expressed in neutrophils from mouse BM, as revealed by Western blotting with the same antibody used to first detect ASPRV1 in skin (ref. 9 and Figure 8B ). Specificity was confirmed by the absence of signal in mononuclear leukocytes and 
Asprv1
-/-neutrophils ( Figure 8B ). In whole spinal cord extracts, Asprv1 mRNA was barely detectable in the absence of inflammation and upon adjuvant injection ( Figure 8C) ; however, it was highly expressed during EAE and strongly correlated with Ly6g mRNA ( Figure 8D ). The abundance of Asprv1 mRNA was remarkable (i.e., higher than or equal to Ly6g mRNA) both in spinal cord extracts and purified neutrophils ( Figure 8D and Supplemental Table 4 ).
To translate our findings to human, we analyzed, by qPCR, blood fractions and postmortem brain samples from people with or without MS. ASPRV1 mRNA was abundant in blood neutrophils in the steady state, but not in B cells, Th cells, monocytes, or unfractionated mononuclear cells ( Figure 8E ). Furthermore, ASPRV1 mRNA was detected in higher amounts in brain lesions from patients with severe MS compared with both normal-appearing white matter and brain lesions from patients with mild or moderate forms of MS ( Figure 8F ). Altogether, our results demonstrate that ASPRV1 is a neutrophil-specific protein in the immune system and can serve as a neutrophil marker in the nervous system both in mice and humans.
ASPRV1 is required for the chronic phase of a B cell-dependent EAE model. To determine whether ASPRV1 contributes to EAE, we immunized ASPRV1-deficient and WT mice with 2 different antigens: the standard MOG peptide and bMOG. bMOG is a potentially novel "humanized" mouse MOG protein, developed by members of our group, that bears the S42P mutation abolishing the immunodominant T cell epitope (amino acids . bMOG can still induce EAE with prominent neutrophilic infiltration, but contrary to MOG peptide (34) , it acts through a B cell-dependent mechanism. This was demonstrated in B1-8
Jκ
-/-mice expressing a single B cell receptor to an irrelevant antigen; these mice did not develop EAE in response to bMOG (Supplemental Figure 2) . Therefore, compared with MOG , bMOG induces a form of EAE that is more similar to MS, as it involves pathogenic B cells.
After immunization with MOG , no difference was observed in EAE incidence and severity between Asprv1 -/-and WT mice ( Figure 9 , A and B, and Table 1 ). In contrast, with bMOG, EAE incidence and acute phase were slightly reduced in the absence of ASPRV1 (Figure 9 , A and B, and Table 1 ). More importantly, the chronic phase was blunted in Asprv1 -/-mice; after a recovery phase culminating around day 7 after onset, WT mice experienced a relapse, whereas Asprv1 -/-mice continued to recover, so that 31% of them showed no more clinical signs by the end of experimentation ( Figure 9B and Table 1) .
To corroborate and explain these symptomatic differences, we performed flow cytometric analysis on spinal cords at different phases of bMOG-induced EAE. At preonset (day 8 after immunization), only neutrophils and macrophages had begun to accumulate (P ≤ 0.0012 with respect to naives) but to a similar extent in Asprv1 -/-and WT mice ( Figure 9C ). At the peak of EAE (day 13 after induction), all types of infiltrating leukocytes reached their maximal numbers; among them, only macrophages were less numerous in the KOs (by ~46%) ( Figure 9C ). More precisely, this reduction predominantly affected the ICAM1 + subpopulation of macrophages ( Figure 9D) , which, by analogy with neutrophils, may be presumed to be extravasated. A similar reduction (43%) in infiltrating macrophages was estimated by stereology using spinal cord sections stained for F4/80 (WT, 83,969 ± 12,287; KO, 47,954 ± 14,025; 2-tailed Student's t test, P = 0.040). No abnormality was noticed in the state of activation of either ICAM1 + macrophages or neutrophils, as inferred from their surface levels of CD45, CD11b, ICAM1, MHCII, and CD86 (data not shown). By the chronic phase (day 21 after immunization), many leukocytes (neutrophils, macrophages, DCs) had left the spinal cord of both mouse strains, leaving behind a sizable population of T cells; in Asprv1 -/-mice, even fewer cells remained, and the number of T cells was only one-sixth that of WT mice ( Figure 9C) .
The lower sensitivity of Asprv1 -/-mice to bMOG was not attributable to a defect in neutrophil migration because no substantial intergenotype difference was seen either in the number of ICAM1 + neutrophils that had infiltrated the CNS tissue at the peak of EAE ( Figure 9D ) or in the number of ICAM1 -neutrophils crawling inside the CNS vasculature ( Figure 9D ) or circulating in blood (Figure 
9E
). This lower sensitivity was not attributable to a defect in T cell primin because the proportion of Th1 and Th17 cells in draining lymph nodes did not differ between the genotypes ( Figure 9F ), which is consistent with previous studies showing that neutrophil depletion does not affect the priming of encephalitogenic T cells (17, 35) . Finally, this phenotype was only associated to ASPRV1 and not observed in mice lacking other neutrophil-specific proteins (IL-36γ and MREG; incidence, P ≥ 0.85; day of onset, P ≥ 0.55; severity over time, P ≥ 0.35; n ≥ 10-12 per group). Overall, our results demonstrate that: (i) ASPRV1 is required both to reach maximum disease severity and to sustain chronic inflammation in response to bMOG, and (ii) ASPRV1 does not significantly affect neutrophil mobilization from BM, adhesion/crawling on the CNS vasculature, or extravasation into meningeal and submeningeal compartments, which is consistent with the normal response of Asprv1 -/-mice to MOG . Therefore, neutrophils exert, most likely in the CNS, a proinflammatory effect via ASPRV1 that is important for perpetuating inflammation specifically in a B cell-dependent form of EAE.
Discussion
The importance of neutrophils for EAE and the mechanism of their recruitment into the CNS have already been extensively investigated (6) , but their phenotype and functions are largely unknown. For the first time to our knowledge, the present study: (i) identifies a surface marker (ICAM1) that distinguishes extravascular from intravascular neutrophils; (ii) identifies a neutrophil-specific marker (ASPRV1) applicable in both mice and humans within the immune and nervous systems; (iii) deciphers the transcriptomic changes undergone by neutrophils after extravasation, hence revealing functional plasticity (e.g., acquisition of macrophage-like immunostimulato- ) after immunization with either MOG or bMOG. Shaded area represents the 95% pointwise CI. For sample size and statistical testing, see incidence in Table 1 . (B) Severity of EAE over time by group versus time from appearance of first symptoms. P value shown on graph was calculated by 2-way ANOVA with repeated measures using rank-transformed scores. Stars indicate differences in post-hoc testing by time point (Wilcoxon test, P < 0.0386). Only mice that had developed EAE are included (see incidence in Table 1 ry and antigen presentation properties); (iv) shows in vivo that neutrophils make intimate physical contacts with T and B lymphocytes at the site of inflammation; (v) specifies the perpetuation of chronic inflammation as one context-dependent function of neutrophils; (vi) ascribes an extraepithelial role to ASPRV1 as a proinflammatory effector; and (vii) introduces a potentially novel humanized myelin antigen (bMOG) that can be used to induce a B cell-dependent form of EAE and to study neutrophil-B cell interactions.
ICAM1 as a marker for extravasated neutrophils. Under healthy conditions, neutrophils continually crawl within the CNS vasculature but do not cross the blood-brain barrier; in EAE, neutrophils become much more numerous, both continuing to patrol within blood vessels and beginning to extravasate into the meninges and parenchyma (6) . Previously, when analyzing CNS samples by flow cytometry, the patrolling and infiltrating neutrophil populations could not be separated. Recent studies have reported ICAM1 expression by neutrophils under certain conditions of activation (36-38); we show here that the great majority of extravasated neutrophils in EAE express ICAM1, but not patrolling neutrophils. By allowing a better adhesion between leukocytes (e.g., via LFA1), ICAM1 facilitates cell-cell interactions such as the formation of immunological synapses (29) . Our results suggest that neutrophils act, at least in part, in a contact-dependent manner in demyelination and provide a surface marker for the study of neutrophil subpopulations.
ASPRV1 as a neutrophil-specific marker in mice and humans. The Ly6G antigen conclusively identifies neutrophils in mice, but no such marker exists in humans. Those that exist (e.g., myeloperoxidase, neutrophil elastase, CD16b, and CD66b) can also be expressed by other myeloid cells and, thus, are not fully specific to neutrophils. This complicates the identification of neutrophils in human tissues (e.g., CNS), since these cells can adopt a macrophage-like phenotype and since their nucleus can be more compacted and, thus, difficult to recognize by conventional microscopy. We propose the use of ASPRV1 as a specific marker for neutrophils in human and mouse tissue samples, with the added benefit of facilitating translation of results from animal models.
Antigen-presenting function of neutrophils. Neutrophils in culture can form immunological synapses (39, 40) and present antigen to T cells (41) (42) (43) (44) , yet the relevance of these nonclassical APCs remains to be shown in vivo. We report here that neutrophils prepare for being APCs at an early stage of development by preforming MHCII mRNA, which can later be translated at the site of inflammation. We also provide the first in vivo evidence to our knowledge for close contacts between neutrophils and T cells within EAE lesions with a redistribution of cell-surface ICAM1. Several types of immunological synapses have been described ex vivo (29) , but more characterization is required to determine to which category the synapses we observed in EAE belong. Since current genetic models cannot specifically delete MHCII in neutrophils, new strategies will be needed to confirm the importance of these synapses. For instance, neutrophils could enhance the anti-MOG Th17 response or contribute to or restrain epitope spreading by ingesting degraded myelin and presenting new epitopes to T cells in either a positive or negative regulatory manner.
ASPRV1-dependent function of neutrophils. The substrate and function of ASPRV1 were previously known only in the context of stratified epithelia (e.g., the stratum corneum of the skin), where it processes profilaggrin and enhances skin hydration (8, 9, 11, 12) . We have now found that ASPRV1 is also expressed in the immune system solely by neutrophils and promotes chronic inflammation in EAE. However, the substrate of ASPRV1 in this new context is unknown, as profilaggrin and other members Figure 9B . Means were compared by Fisher's exact test (for recovery), by the logrank test (for incidence and mortality), or otherwise by Wilcoxon test.
of its family are not expressed in neutrophils (Supplemental Table 1 ) and have not been reported in the immune and nervous systems. Since ASPRV1 was ostensibly acquired from a retrotransposon sometime around the advent of mammals (45) , the selective expression of ASPRV1 in neutrophils may be associated to a mammal-specific function of neutrophils. By comparison with other aspartic proteases (e.g., cathepsin D, DNA damage-inducible protein 1, pepsin, renin), ASPRV1 may be involved in an intracellular or extracellular process such as endosomal proteolysis, antigen processing for the MHCII pathway, or proteolytic activation of inflammatory mediators.
bMOG as an antigen for EAE induction. B cells contribute to MS and NMOSD in 2 major ways: by secreting autoantibodies and by stimulating the development of autoreactive Th cells via antigen presentation and secretion of cytokines (e.g., IL-6, GM-CSF, and IL-15) (46) . Similarly, B cells are essential for the development of EAE when induced with either bMOG, as demonstrated herein, or human MOG protein (47) . However, in the traditional MOG model, B cells play no such role, instead acting as beneficial, regulatory cells, since depleting them exacerbates the symptoms (14, (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) . This is possibly because DCs and macrophages can only present the immunodominant MOG epitope to T cells, whereas B cells can process and present several epitopes, thereby mounting a more diversified response; by mutating the 35-55 epitope in bMOG, B cells become necessary APCs for T cell activation. The advantages of using bMOG are 2-fold: first, compared with the traditional MOG peptide, bMOG represents an improved model for investigating B cell-dependent responses, which is especially important given the recent success of B cell depletion therapy for MS (46) ; second, compared with human MOG, bMOG differs from mouse MOG by only a single amino acid, thus excluding possible confounding effects of multiple mutations and unwanted immunogenicity. Use of bMOG should help mechanistic studies of how the immune response can drift from foreign to self-epitopes.
Conclusion. Long considered a black sheep in the field of autoimmune demyelination, neutrophils should rather be seen as an essential component of a cooperative network of immune cells interacting chemically and physically with one another. By linking an ASPRV1-dependent function of neutrophils to the progression of a B cell-dependent form of EAE, our study suggests that neutrophils could be engaged in a unique way in some forms and stages of demyelinating diseases. More specifically, our study points to a possible role for neutrophils as downstream effectors of B cells in autoimmunity. Furthermore, our work provides new tools (markers, transcriptomic profiles, transgenic models, bMOG) to explore the many facets of neutrophils. In particular, ASPRV1 could prove a useful biomarker for identifying the presence of neutrophils in biological samples for basic research and clinical diagnosis. Future challenges include finding the substrate(s) of ASPRV1 in the immune system, explaining why neutrophils exert a differential effect in B cell-dependent EAE, and determining whether ASPRV1 could be targeted for the treatment of NMOSD, some forms of MS, and other immune disorders.
Methods
Human brain samples. Snap-frozen postmortem brain samples from MS and control patients were obtained from the Multiple Sclerosis Society Tissue Bank at the Imperial College London (London, United Kingdom). Additional samples from a patient with severe rebound MS activity after natalizumab withdrawal (58) was obtained from the University of Montreal Hospital Research Center. Biopsies were classified as acute active lesion (stage 1 and 2), chronic active lesion (stage 3 and 4), chronic inactive lesion (stage 5), or normal appearing white matter, as described previously (59) . Lesions were scored for severity based on the degree of demyelination and inflammation, as described previously (59) . Frozen sections were cut with a cryostat to obtain approximately 20 mg of tissue, which was homogenized in TRI-reagent (MilliporeSigma) and processed with the EZ-10 Spin Column Animal Total RNA Mini-prep Kit (Bio Basic) to extract RNA for qPCR. Additional sections were used for histology.
Human blood samples. Healthy volunteer blood was layered on top of lymphocyte separation medium (Wisent Bioproducts) and centrifuged for 20 minutes at 600 g. The top cell fraction, enriched in PBMCs, was used directly or processed with the EasySep Human CD4 + T Cell, B Cell or Monocyte Isolation kits; the lower fraction, enriched with granulocytes, was processed with the EasySep Direct Human Neutrophil Isolation kit, according to the manufacturer's instructions (StemCell Technologies). RNA was purified from cell fractions using Aurum Total RNA kit (Bio-Rad).
Animals. C57BL/6, Ai6 (21), and H2-Ab1-floxed (33) mice were obtained from The Jackson Laboratory. Asprv1
-/-(9), Il1f9 -/- (25) , Mreg -/- (60) , and Catchup (20) mice (C57BL/6 background) were derived from previously established colonies. B1-8 mice (61) with a homozygous deletion of the Jκ locus (62) were provided by Ann Haberman (Yale University, New Haven, Connecticut, USA). Genotypes were confirmed by PCR using the primers listed in Supplemental Table 5 . Experiments were performed under specific pathogen-free conditions on mice aged 8-10 weeks. bMOG production. The pET-32 MOG tag vector (63) was mutated by PCR using the following primers: 5′-TACCGTCCGCCGTTTTCTCGCGTTGTTCACC-3′ and 5′-AAACGGCGGACGGTACCAGC-CAACTTCCAT-3′. The resulting vector was sequenced to confirm the insertion of the S42P mutation and used to produce bMOG according to a previously described protocol (64) . Final concentration was set to 5 mg/ml with no detectable impurities, as measured by Bradford assay and SDS-PAGE.
EAE induction. Mice were s.c. injected into both flanks with a total of 200 μl of emulsion containing either 300 μg of MOG (Synpeptide) or 500 μg of bMOG (see above) dissolved in saline and mixed with an equal volume of complete Freund's adjuvant containing 500 μg of killed Mycobacterium tuberculosis H37 RA (Difco Laboratories). Mice were also i.p. injected with 20 μg/kg of PTX (List Biological Laboratories) immediately and 2 days after immunization.
Evaluation of EAE symptoms. Mice were weighed and scored daily as follows: 0, no visual sign of disease; 0.5, partial tail paralysis; 1, complete tail paralysis; 1.5, weakness in one hind limb; 2, weakness in both hind limbs; 2.5, partial hind limb paralysis; 3, complete hind limb paralysis; 3.5, partial forelimb paralysis; 4, complete forelimb paralysis; 5, dead or killed for humane reasons.
Flow cytometry. Blood samples were harvested by cardiac puncture in EDTA-treated cuvettes and treated with ammonium chloride solution (Stemcell Technologies) to remove erythrocytes. Mice were then anesthetized and exsanguinated by cardiac perfusion with saline. Spinal cords were harvested, minced with razor blades in Dulbecco's PBS, digested for 45 minutes at 37°C with 0.13 U/ml Liberase TM (Roche Diagnostics) and 50 U/ml DNase (MilliporeSigma) in Dulbecco's PBS, filtered through 40-μm cell strainers, and then separated from myelin debris by centrifugation at 1,000 g in 35% Percoll (GE Healthcare). Lymph nodes were harvested and passed through 40-μm cell strainers. For immunostaining, cells were incubated on ice for 5 minutes with rat anti-CD16/CD32 antibody (BD Biosciences, clone 2.4G2, 5 μg/ ml) and Fixable Viability Dye eFluor 506 or 455UV (eBioscience, 1:1,000), then for 30 minutes with combinations of primary antibodies (Supplemental Table 6 ). Cells were washed and resuspended in PBS before being analyzed/sorted with a FACSAria II flow cytometer (BD Biosciences). Before analysis, the following quality control checks were performed using FlowJo (Tree Star Inc.): debris were removed using FSC-A and SSC-A, doublets were removed using FSC-A and FSC-H, and all dead cells that were positive for the fixable viability dye eFluor 455UV (eBioscience) were removed. Gates were based on fluorescence-minus-one controls. CNS cell counts were normalized to CD45 -cells, whose numbers are proportional to the sample volume, to control for variation in cell yield.
ELISpot. To detect MOG-specific plasma cells in BM, 96-well plates were coated overnight at 4°C with 0.5 μg mouse MOG . Wells were blocked with 1% (wt/vol) BSA in PBS, then incubated with BM cells at 37°C with 5% CO 2 . Spots were detected using a goat alkaline phosphatase-conjugated anti-mouse IgG antibody (MABTECH) and 5-bromo-4-chloro-3-indolyl-phosphate substrate (MilliporeSigma), before being counted under a dissection microscope (Leica M80).
Microarray analysis. Total RNA was extracted from FACS-purified cells using the miRNeasy Micro Kit (Qiagen). RNA (75 ng) was used to produce biotinylated single-strand cDNAs using the Affymetrix GeneChip WT Plus Reagent Kit. The cDNAs were hybridized to Affymetrix Mouse Gene 2.0 ST arrays for 16 hours at 45°C with constant rotation at 60 rpm. The arrays were washed and stained using the Affymetrix GeneChip Fluidics Station 450 and then read using the Affymetrix GeneChip Scanner 3000 7G. Data were processed using the RMA algorithm in Affymetrix Expression Console and filtered in Microsoft Excel. Using the MeV software (TIGR), filtered data (intensity > 100 in at least 1 group; SD > 100) were log 2 -transformed and analyzed by hierarchical clustering using Spearman correlation. KEGG (https:// david-d.ncifcrf.gov) and Ingenuity Pathway Analysis (Qiagen) were used to identify enriched pathways.
qPCR. Total RNA was extracted from cells, spinal cord, and blood using EZ-10 Spin Column Animal Total RNA Mini-preps Kit (Bio Basic), TRI-reagent (MilliporeSigma), and RNeasy Protect Animal Blood Kit (Qiagen), respectively. First strand cDNA was generated from 1-5 μg of RNA using Superscript III (Invitrogen) with random hexamers and 20-mer oligo-dT primers; it was then purified using the GenElute PCR Clean-Up Kit (MilliporeSigma). The product (20 ng) was analyzed using the LightCycler 480 system with the SYBR Green I Master mix and primers listed in Supplemental Table 7 according to the manufac-turer's instructions (Applied Biosystems). The PCR conditions consisted of 45 cycles of denaturation (10 seconds at 95°C), annealing (10 seconds at 60°C), elongation (14 seconds at 72°C), and reading (5 seconds at 74°C). The number of mRNA copies was determined using the second derivative method (65) .
Western blotting. BM cells were collected by flushing out femurs with 10 ml of HBSS (Wisent Bioproducts), filtered through 70-μm mesh, resuspended in HBSS containing 45% Percoll (GE Healthcare), and centrifuged at 1,600 g for 30 minutes over a 4-level Percoll density gradient (45%, 55%, 65%, 81%). Cell layers (mononuclear cells from the top and 45%-55% interface; neutrophils from the 65%-81% interface) were retrieved and lysed by sonication (3 × 5 seconds) in 50 μl RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1× protease and phosphatase inhibitor cocktails [MilliporeSigma, P8340 and P5726], pH 8.0). Protein samples (20 μg) were boiled for 5 minutes in Laemmli buffer (50 mM Tris-HCl, 2% SDS, 6% β-mercaptoethanol, 10% glycerol, 12.5 μg/ml bromophenol blue), resolved on 15% SDS-polyacrylamide gel (Bio-Rad Mini-Protean II), and transferred to a polyvinylidene difluoride membrane for 45 minutes at 4°C and 100 V in transfer buffer (25 mM Tris, 200 mM glycine) containing 20% methanol. The membrane was blocked for 30 minutes at room temperature in TSM (10 mM Tris, 150 mM NaCl, 5% nonfat dry milk, 0.1% Tween 20, pH 7.4), and incubated for 1 hour at room temperature and then overnight at 4°C in 7 ml of TSM containing polyclonal rabbit antibody to ASPRV1 C-terminus (9) (1:1,000). The membrane was washed 4 times in TSM for 5 minutes and then incubated for 1 hour at room temperature with horseradish peroxidase-conjugated goat anti-rabbit antibody (111-035-144, 1:2,500; Jackson ImmunoResearch). The membrane was again washed 4 times in TSM, twice in TS (10 mM Tris, 150 mM NaCl, pH 7.4), and once briefly in water, before being incubated for 60 seconds with 1 ml Western Lightning chemiluminescence substrate (PerkinElmer); it was then blotted dry. The chemiluminescent signal was captured on Carestream Bio-Max Light Film (Kodak), which was scanned at 800 dpi and adjusted for contrast and brightness with Photoshop (Adobe). To control for protein loading, the membrane was rinsed overnight in TS and blotted for β-actin by 1-hour incubations at room temperature first in mouse anti-β-actin antibody (MAB1501, 1:5,000; Millipore, clone C4) and then in goat anti-mouse antibody (115-035-003, 1:2,500; Jackson ImmunoResearch).
Histology. Mice were transcardially perfused with saline, followed by ice-cold 4% paraformaldehyde in phosphate buffer, pH 7.4, over 10 minutes. Spinal cords were removed, postfixed for 4 hours at 4°C, and then cryoprotected overnight in 50 mM potassium phosphate-buffered saline supplemented with 20% sucrose. Series of sections were cut at 14 μm using a cryostat and stored at -20°C until analysis. Immunofluorescence was performed, as described previously (66) , using combinations of primary antibodies (Supplemental Table 8 ). Slides were counterstained for 1 minute with 2 μg/ml DAPI and then mounted with coverslips no. 1.5H and ProLong Diamond (Molecular Probes; refractive index, 1.47). Macrophage number (F4/80 + ) was estimated using a Stereo Investigator system (Microbrightfield) on a Nikon E800 microscope by the optical fractionator method, taking into account sampling frequency, magnification, and section thickness. To this end, inflammatory foci were traced using a ×10/0.45 objective with DAPI and sampled using a ×100/1.40 objective with the following parameters: distance between counting frames, 90 × 90 μm; frame size, 40 × 40 × 8 μm. Cells were counted if they were at least partially within the 3D counting frame and did not touch the exclusion lines.
Confocal and STED microscopy. Confocal images were acquired with a Leica TCS SP8 STED ×3 microscope (equipped with white-light laser, 405-nm diode laser, and HyD detectors) by sequential scanning using the following settings: objective, HC/PL/APO ×63/1.40 oil or ×10/0.4 dry; immersion oil, Leica Type F (refractive index, 1.518); scan speed, 600 Hz; line average, 2-4; and time gate, 0.3-6.0 ns. Laser power and gain were set to optimize signal-to-noise ratio and avoid saturation using the QLUT Glow mode. Sizes of pixel, pinhole, and z-step were set to optimize resolution or to oversample in the case of images to be deconvolved. STED was performed with a 775-nm depletion laser and the following adapted settings: objective, PL/APO ×100/1.40 oil STED White; line average, 6-8; time gate, 0.5-6.0 ns; STED 3D, approximately 50%-75%; and depletion laser intensity, 60% (Alexa Fluor 594) or 30% (Atto 647N). Deconvolution was performed with Huygens Professional (Scientific Volume Imaging) using a theoretical point spread function, manual settings for background intensity, and default signal-to-noise ratio. Three-dimensional reconstruction was performed with LAS X 3D Visualisation (Leica). Color balance, contrast, and brightness were adjusted with Photoshop (Adobe).
Statistics. Unless otherwise indicated, data are expressed as mean ± SEM. In general, means were compared with nonparametric (Wilcoxon, Kruskal-Wallis) or parametric tests (2-tailed Student's t test, 2-way
